OBIO
Orchestra BioMed Holdings Inc.
5.80$
-3.2%
vs. previous close
Closing price · As of: Oct 6, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 9.8% | 31.7% | 17.4% | 5.7% | 6.9% | 22.9% | 5.1% | 5.5% | 5.7% | 0.2% | 83.6% | 28.4% | 0.7% | |
| 90.2% | 68.3% | 82.6% | 94.3% | 93.1% | 77.1% | 94.9% | 94.5% | 94.3% | 99.8% | 16.4% | 71.6% | 99.3% | |
| 2,042.5% | 3,248.5% | 1,469.7% | 1,430.1% | 1,174.8% | 4,336.4% | 1,553.2% | 1,657.1% | 1,629.2% | 54.4% | 14,346.4% | 18,852.3% | 197.7% | |
| 1,514.1% | 1,597.3% | 951.1% | 831.2% | 574.1% | 2,332.4% | 721.5% | 749.3% | 824.4% | 23.6% | 5,793.6% | 6,623.9% | 83.2% | |
| 3,556.6% | 4,832.1% | 2,408.9% | 2,261.3% | 1,748.8% | 6,668.8% | 2,274.8% | 2,406.3% | 2,453.5% | 78.0% | 20,085.5% | 25,476.1% | 280.7% | |
| -3,466.3% | -4,763.7% | -2,326.3% | -2,167.0% | -1,655.7% | -6,591.7% | -2,179.8% | -2,311.8% | -2,359.2% | 21.8% | -20,069.1% | -25,404.5% | -181.4% | |
| – | 134.0% | – | – | – | – | – | 4.3% | 59.8% | 2.5% | 746.4% | 2,009.1% | 12.1% | |
| -3,178.0% | -4,892.4% | -2,171.5% | -2,054.0% | -1,562.9% | -6,385.4% | -2,160.7% | -2,316.1% | -2,419.0% | 20.2% | -18,810.0% | -26,994.3% | -184.6% | |
| -288.3% | 1,039.3% | 5.0% | – | – | -12.1% | – | – | – | – | – | – | – | |
| -3,178.0% | -4,892.4% | -2,171.5% | -2,054.0% | -1,562.9% | -6,385.4% | -2,160.7% | -2,316.1% | -2,419.0% | 20.2% | -18,810.0% | -26,994.3% | -184.6% | |
| -3,161.1% | -4,864.9% | -2,159.5% | -2,044.5% | -1,555.2% | -6,352.2% | -2,151.2% | -2,306.5% | -2,409.6% | 22.9% | -17,981.8% | -26,885.2% | -178.6% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 6, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.